CBD Drug Interactions: A Clinical Reference Guide
CYP enzyme inhibition, clinical significance, and monitoring recommendations
CBD is a potent inhibitor of multiple CYP enzymes, creating clinically significant drug interactions with dozens of commonly prescribed medications. This guide covers the mechanisms, affected drug classes, and monitoring recommendations for clinicians and patients.
Why CBD Causes Drug Interactions
CBD is metabolized primarily by CYP2C19 and CYP3A4 enzymes in the liver. More importantly, CBD is also a potent inhibitor of these same enzymes — meaning it slows down the metabolism of other drugs that use the same pathways. When CBD inhibits CYP2C19 or CYP3A4, co-administered drugs are metabolized more slowly, leading to higher blood levels and potentially increased effects and toxicity.
CBD also inhibits CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP2D6 to varying degrees. The clinical significance of these interactions depends on the therapeutic index of the co-administered drug (narrow therapeutic index drugs are most concerning), the dose of CBD, and individual patient factors including genetic CYP polymorphisms.
Antiseizure Medications: The Most Critical Interactions
The most clinically significant CBD drug interactions are with antiseizure medications — ironic given that CBD is primarily used for epilepsy. CBD inhibits CYP2C19, which metabolizes clobazam to its active metabolite N-desmethylclobazam (NCLB). CBD co-administration increases NCLB levels by 3-5 fold, significantly increasing sedation and other adverse effects. Clobazam dose reduction is often required when starting Epidiolex.
CBD also increases valproate levels and may increase the risk of valproate-induced liver toxicity — a combination that requires careful monitoring of liver function tests. Other antiseizure medications affected include phenytoin, carbamazepine, and topiramate. Clinicians managing epilepsy patients on Epidiolex should review all antiseizure medications for potential interactions.
Blood Thinners: Warfarin and Direct Oral Anticoagulants
CBD inhibits CYP2C9, which metabolizes warfarin. Multiple case reports describe significantly elevated INR (international normalized ratio) in patients taking warfarin who started CBD. This interaction can increase bleeding risk. Patients on warfarin who use CBD require more frequent INR monitoring and likely warfarin dose reduction.
Direct oral anticoagulants (DOACs) including rivaroxaban, apixaban, and edoxaban are metabolized by CYP3A4 and P-glycoprotein — both inhibited by CBD. Increased DOAC levels could increase bleeding risk. Clinical data on CBD-DOAC interactions are limited, but caution is warranted.
Psychiatric Medications
CBD inhibits CYP2D6, which metabolizes many antidepressants (fluoxetine, paroxetine, venlafaxine, tricyclics) and antipsychotics (haloperidol, risperidone, aripiprazole). Increased levels of these medications can cause adverse effects including QT prolongation, sedation, and extrapyramidal symptoms. Patients on psychiatric medications who use CBD should be monitored for signs of medication toxicity.
CBD also inhibits CYP3A4, which metabolizes many benzodiazepines (diazepam, alprazolam, midazolam). Increased benzodiazepine levels can cause excessive sedation and respiratory depression. This interaction is particularly concerning in patients using CBD for anxiety who are also prescribed benzodiazepines.
Immunosuppressants and Oncology Drugs
Tacrolimus, cyclosporine, and sirolimus — immunosuppressants used after organ transplantation — are metabolized by CYP3A4. CBD can significantly increase their levels, risking toxicity (nephrotoxicity, neurotoxicity). Case reports of tacrolimus toxicity in transplant patients using CBD have been published. Transplant patients should be strongly advised to disclose any CBD use to their transplant team.
Many chemotherapy agents are also CYP3A4 substrates. CBD could increase levels of docetaxel, paclitaxel, irinotecan, and others, potentially increasing toxicity. Oncology patients using CBD should always disclose this to their oncologist before starting chemotherapy.
Practical Monitoring Recommendations
For clinicians managing patients who use CBD: (1) Always ask about CBD use — many patients do not consider it a "medication" and may not volunteer this information; (2) For patients on narrow therapeutic index drugs (warfarin, antiseizure medications, immunosuppressants, digoxin), check drug levels before and after starting CBD; (3) For warfarin patients, check INR within 1–2 weeks of starting CBD; (4) For antiseizure medication patients, monitor for increased adverse effects and consider dose reduction; (5) Use the lowest effective CBD dose to minimize interaction risk; (6) Be aware that commercial CBD products have variable and often inaccurate labeling — actual CBD content may differ significantly from labeled content.
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making treatment decisions. See our editorial standards.